CD81 is a novel immunotherapeutic target for B cell lymphoma
Abstract
The tetraspanin CD81 was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target CD81, has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft model as effectively as rituximab, which is a standard treatment for B cell lymphoma. Importantly, unlike rituximab, which depletes normal as well as malignant B cells, 5A6 selectively kills human lymphoma cells from fresh biopsy specimens while sparing the normal lymphoid cells in the tumor microenvironment. The 5A6 antibody showed a good safety profile when administered to a mouse transgenic for human CD81. Taken together, these data provide the rationale for the development of the 5A6 mAb and its humanized derivatives as a novel treatment against B cell lymphoma.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 23, 2019
- Source ID
- 10.1084/jem.20190186
Entities
People
- Caroline Duault
- Chiung-chi Kuo
- Debra K. Czerwinski
- Felipe Vences-catalán
- Noemi Andor
- Ranjani Rajapaksa
- Ronald Levy
- Shoshana Levy
Organizations
- National Institutes of Health
- Stanford Cancer Institute
- Stanford University
- United States Department of Defense